A'cancld

30. A DNA vaccine protective against naturally occuring or genetically engineered *Yersinia pestis* subcutaneous and aerosol infection comprising a recombinant DNA construct according to claim 8 in a pharmaceutically acceptable excipient in a pharmaceutically acceptable amount.--

REMARKS

Entry of the foregoing amendments and following remarks is respectfully requested.

The specification has been amended to include the proper strain of *Y. pestis* used to isolate the V antigen. Applicants appologize for the oversight. The amendment finds support in the Sequence Listing as originally filed. Entry of the amendment to the specification is kindly requested.

Responsive to the restriction requirement, Applicants hereby elect with traverse the invention of Group I, claims 1-17, drawn to the DNA and method of use of the DNA and reserve the right to file a divisional application on the nonelected claims in the event the restriction requirement is made final. The newly proposed claim 29, drawn to a protein produced by the method of claim 17 of Group I and new claim 30, drawn to a DNA vaccine using the recombinant DNA of claim 8 of Group I, are proposed as part of Group I since both claims are drawn to either a product of an elected method, or a use of an elected DNA construct.

Entry of the new claims in Group I and an early action on the merits are respectfully requested.

Respectfully submitted,

By S.Pratt Reg. No. 39,441
for John F. Moran
Reg. No. 26,313

U.S. A. MRMC
504 Scott Street
Fort Detrick, MD 21702-5012
ATTN: MCMR-JA (John Moran-Patent Atty)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the

Commissioner of Patents
Washington, D.C. 20231

on August 8, 1997.

By S.Pratt
Sana A. Pratt
Reg. No. 39,441